Vizsgálati helyszín
Teikyo University Hospital
tabashi City, 173 8606, JapánMég nincs intézményhez kötve
- 17futó vizsgálat
- 13lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 30 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis17 vizsgálat
- 1. fázis1 vizsgálat
- 2. fázis1 vizsgálat
- 2/3. fázis1 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Lezárult13 vizsgálat
- Fut, nem toboroz11 vizsgálat
- Toboroz6 vizsgálat
- Fő szponzor
- Janssen Research & Development, LLC7 vizsgálat
- Amgen4 vizsgálat
- Janssen Pharmaceutical K.K.3 vizsgálat
- Takeda3 vizsgálat
- Bristol-Myers Squibb2 vizsgálat
- és még 10
Futó vizsgálatok
Fut, nem toboroz
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
NCT07230860· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Clinical Evaluation of AMJ-401
NCT07373353· Abbott Medical Devices· Forrás
Toboroz
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT07250802· 3. fázis· Takeda· Forrás
Contact: Yayoi Tada (principal investigator)
Toboroz
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Yayoi Tada, Site 0391
Fut, nem toboroz
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433· 3. fázis· Amgen· Forrás
Toboroz
Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure
NCT07125417· 4. fázis· OCEAN-SHD Study Group· Forrás
Contact: Yusuke Watanabe
Toboroz
Prevail Global Study
NCT06535854· Medtronic Vascular· Forrás
Contact: Yusuke Watanabe (principal investigator)
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
NCT06531109· Pfizer· Forrás
Fut, nem toboroz
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
NCT06295692· 3. fázis· Janssen Pharmaceutical K.K.· Forrás
Fut, nem toboroz
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06143878· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565· 2/3. fázis· Biogen· Forrás
Toboroz
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
NCT04951622· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT04772079· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Yayoi Tada, Site 0034
Fut, nem toboroz
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03950232· 3. fázis· Pfizer· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study
NCT06412848· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Forrás
Lezárult
A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
NCT06323356· 3. fázis· Takeda· Forrás
Lezárult
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
NCT06088043· 3. fázis· Takeda· Forrás
Lezárult
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis
NCT05565560· 3. fázis· Amgen· Forrás
Lezárult
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
NCT05398445· 3. fázis· Amgen· Forrás
Lezárult
Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)
NCT05174065· 3. fázis· Amgen· Forrás
Lezárult
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer
NCT06542731· 1. fázis· Ono Pharmaceutical Co., Ltd.· Forrás
Lezárult
A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan
NCT04459507· Janssen Pharmaceutical K.K.· Forrás
Lezárult
Registry of Asthma Patients Initiating DUPIXENT®
NCT04287621· Regeneron Pharmaceuticals· Forrás
Lezárult
Safety and Effectiveness of Agent Paclitaxel-Coated PTCA Balloon Catheter. (AGENT Japan SV)
NCT04058990· Boston Scientific Corporation· Forrás
Lezárult
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
NCT04034095· Janssen Pharmaceutical K.K.· Forrás
Lezárult
Clinical Trial of Cilostazol Eluting Stent System (CES-1) in De Novo Coronary Artery Lesions
NCT03189641· JIMRO Co., Ltd.· Forrás
Hibát jelzek